PARAMUS, N.J., Jan. 8, 2013 \/PRNewswire\/ -- Proteonomix, Inc. (the \"Company\")(Symbol PROT), a biotechnology company (the \"Company\") focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that the University of Medicine & Dentistry of New Jersey (UMDNJ) in conjunction with the Company has commenced enrollment of patients with End Stage Liver Disease (ESLD) in its clinical trial of UMK-121. <\/p>\n
Michael Cohen, President and CEO of the Company, stated; \"We have began to screen new patients for the UMK-121 trial and have enrolled our first candidate into the trial. We expect to enroll more patients in the upcoming months. The treatment of our first patient on the UMK-121 trial is a major step forward for the company and demonstrates the company's ability to move new therapies into therapeutic testing. Two additional trials of UMK-121 are presently being developed in cancer and heart diseasewhich we intendto initiate in 2013.\" <\/p>\n
About Proteonomix, Inc. <\/p>\n
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Proteonomix family of companies includes Proteoderm, StromaCel, PRTMI and THOR Biopharma. Proteoderm is a wholly owned subsidiary that has developed an anti-aging line of skin care products. StromaCel develops therapeutic modalities for the treatment of cardiovascular disease and for treatment of patients who have suffered post-myocardial infarction. Proteonomix Regenerative Translational Medicine Institute, Inc. (PRTMI) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Additional information is available at http:\/\/www.proteonomix.com<\/a> and http:\/\/www.proteoderm.com<\/a>. <\/p>\n Forward-looking statements: <\/p>\n Certain statements contained herein are \"forward-looking statements\" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made. <\/p>\n <\/p>\n More: PARAMUS, N.J., Jan. 8, 2013 \/PRNewswire\/ -- Proteonomix, Inc. (the \"Company\")(Symbol PROT), a biotechnology company (the \"Company\") focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that the University of Medicine & Dentistry of New Jersey (UMDNJ) in conjunction with the Company has commenced enrollment of patients with End Stage Liver Disease (ESLD) in its clinical trial of UMK-121 Continue reading
\nProteonomix Updates Status Of UMK-121 Testing<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"